ArticleJournal of neuro-oncology2026
Multiomics reveals the mechanism of KNG1 in promoting tumor progression in adamantinomatous craniopharyngioma.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeAdamantinomatous craniopharyngioma (ACP) are rare and histologically benign but clinically challenging neoplasms. The aim of this study was to investigate the molecular genetic and proteomic alterations in the tumor to identify potential therapeutic targets for ACP.
methodsSanger sequencing characterized mutations in 20 craniopharyngiomas. Serum proteomics by iTRAQ-based LC-MS/MS compared ACP patients with healthy controls. KNG1 expression was examined in tumor tissues (RT‑qPCR, Western blot) and serum (ELISA), followed by clinical correlation analysis. Molecular mechanisms of KNG1 were investigated using snRNA‑seq, spatial transcriptomics (ST), and immunofluorescence. To investigate whether KNG1 functions through the PI3K-AKT pathway, we performed lentiviral overexpression in ACP primary cells and applied a PI3K-AKT activator. The resulting impact on proliferation, migration, invasion, and mitochondrial integrity was then examined using a suite of functional assays.
resultsCTNNB1 missense mutations were identified in 38.8% of ACPs. Subsequently, KNG1 was found downregulated at both tissue and serum levels, with the latter inversely correlating with tumor volume. Mechanistically, snRNA-seq, ST and immunofluorescence analyses suggested the involvement of the PI3K-AKT pathway. Functional studies confirmed that KNG1 overexpression attenuated PI3K-AKT signaling, curbed tumor growth, migration and invasion, and promoted mitochondrial damage, all of which were rescued by PI3K-AKT activation.
conclusionOur findings indicate that downregulation of KNG1 is associated with ACP progression, potentially through its interaction with PI3K-AKT pathway activation. These results support the exploration of KNG1 and PI3K-AKT signaling as potential therapeutic targets in ACP, and suggest that serum KNG1 may serve as a candidate biomarker for monitoring disease progression.
Indexed as
Identifiers
41489673What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.